Objectives: Li Fraumeni syndrome is an autosomal dominant cancer syndrome due to a germline mutation in the p53 tumor suppressor gene. It results in multiple primary neoplasms in children and adults. A common question when faced with a Li Fraumeni patient who develops multiple primary cancers and/or recurrences is what is the proper treatment? Data suggests that ionizing radiation exposure increases the incidence of second malignancies in the Li Fraumeni population. Therefore, how much surgery can a cancer patient tolerate and still derive benefit from it?
O ver a decade ago, Dr Blake Cady stated that in surgical oncology, "Biology is King; selection of cases is Queen, and the technical details of surgical procedures are the Princes and Princesses of the realm who frequently try to overthrow the powerful forces of the King or Queen, usually to no longterm avail, although with some temporary apparent victories." 1 Although this statement was proven correct on many occasions in the last century, recent technical advances, new surgical techniques, revised staging schemes, improved early diagnosis, and more efficacious chemotherapy have resulted in reexamination of this historically important dictum. We report a case of a patient with Li Fraumeni syndrome (LFS) with an adrenocortical hepatic metastasis and a synchronous new primary ampullary cancer. After extensive review of the literature, we propose an aggressive surgical approach for patients with multiple cancers in the setting of LFS. Relevant literature and treatment are discussed below.
MATERIALS AND METHODS
During routine screening endoscopy, an asymptomatic 54-year-old female with known LFS was found to have a new ampullary mass in 2010. Biopsies revealed adenocarcinoma, moderately differentiated and invasive. Immunohistochemistries were performed and tumor cells were positive for CKC, CDX-2, CK20, and negative for CK7, ER, PR, TTF-1, BRST-2. These findings supported a gastrointestinal primary. Staging computed tomography imaging demonstrated a 6 cm hepatic mass and a 1.6 cm ampullary mass (Fig. 1A) . Corresponding positron emission tomography (PET) images showed the hepatic mass to have a standardized uptake value of 9.7 (Fig. 1B ). There were no other areas of significant PET avidity. The synchronous hepatic mass was biopsy proven to be metastatic adrenocortical carcinoma (ACC).
The patient's oncologic and surgical histories date back to 1987 (24 y before the current presentation, Table 1 ) when she was diagnosed with intraductal carcinoma of the breast. Subsequently, she developed recurrent breast cancer along with multiple other primary cancers: ACC (1989), right chest wall malignant fibrous histiocytoma (1995), multiple basal cell carcinomas, and ampullary cancer. In addition to these 5 different primary cancers our patient had metastatic ACC to the lung and the liver (1992, 1994, 1997, and 2000) . In 2008 she was diagnosed with LFS by documenting a germline mutation in the p53 tumor suppressor gene. Relevant surgical history was: open left adrenalectomy, nephrectomy, and splenectomy for ACC and prophylactic total abdominal hysterectomy and bilateral salpingo-oophorectomy. Relevant hepatic interventions included open nonanatomic wedge resection of segments V and IVB with cholecystectomy, margin status negative but <2 mm. This was followed by a recurrence 3 years later and an extended right hepatectomy (metastatic ACC). The patient recurred in her hepatic remnant after 3 years and underwent percutaneous radiofrequency ablation of a solitary hepatic lesion (metastatic ACC). One year later, due to increasing size of this hepatic lesion she underwent open radiofrequency ablation of this solitary lesion (metastatic ACC).
The patient had an excellent performance status with an ECOG score of 0. Tumor markers were: CEA 4.7 (range, 0.8 to 3.4), AFP 7.0 (range, 0.6 to 6.6), CA19-9 8 (range, 0 to 55), CA15.3 27 (range, 0 to 30), and CA 27.9 25 (range, 0 to 38). All other laboratory values including adrenocortical releasing hormone, serum cortisol, and plasma metanephrines were within normal limits. On review of the patient's hepatic anatomy, a solitary tortuous portal vein and solitary hepatic vein were found, secondary to previous procedures and hepatic hypertrophy (Fig. 1A) . Of note, the ACC hepatic metastasis was abutting the solitary portal vein.
RESULTS

Surgical Approach
After appropriate staging workup and multidisciplinary discussion, a surgical approach to render the patient disease free was decided. We brought the patient to the operating theater, 3 attending surgeons and 1 surgical fellow participated. Initially an extensive lysis of adhesions was performed after which, we focused our attention on resection of the hepatic mass. Intraparenchymal aspects of the tumor were identified by intraoperative ultrasound, palpation, and confirmatory frozen section biopsy. Inflow control was then obtained ( Fig. 2A) . Because of the patient's previous hepatic surgeries and resulting perihepatic adhesions, we felt it unsafe to dissect her solitary hepatic vein; therefore, we did not gain outflow control. Consistent with imaging, the tumor was found to be directly adjacent and abutting for 6 cm the patient's solitary inflow, intrahepatic portal vein, which was freed by meticulous dissection. A nonanatomic wedge resection was then performed. Pringle maneuver lasted 9 minutes. As this was a nonanatomic resection, her future liver remnant would be >85% of her current remnant (what was left after her extended right hepatectomy). After the hepatic resection, we proceeded with a standard pancreaticoduodenectomy (PD). All resection margins were grossly clear. Total procedural time was 13 hours and approximate blood loss was 1.5 L.
Pathology
On microscopic examination the hepatic mass was confirmed to be metastatic ACC with the patient's primary. The intrahepatic portal vein margin was focally involved microscopically. The ampullary mass was moderately differentiated ampullary adenocarcinoma confined to the Ampulla of Vater, stage I. All resection margins were negative for tumor.
Follow-Up
The patient tolerated the procedure well and was discharged on a low fat diet on postoperative day 17. Early in her postoperative course she was found to have a superficial wound infection at the lateral aspect of her chevron incision. This was opened and healed by secondary intention. She was followed with computed tomography imaging every 3 months and received 12 cycles of adjuvant cisplatin. Because of this regimen, the patient developed grade 3 peripheral neuropathy after cycle 10. Follow-up is now at 23 months and imaging remains stable. Patient has no nausea, vomiting, or bowel dysfunction and her weight remains stable.
DISCUSSION
LFS is a rare autosomal dominant neoplastic syndrome characterized by a wide spectrum of primary malignancies in children and adults. This syndrome has now been linked to germline mutations of p53, a tumor suppressor gene on the short arm of chromosome 17. These mutations allow for the accumulation of genetic damage, in effect leading to genomic instability and neoplastic formation. 2 Criteria for LFS have been developed and include: (1) a proband with any bone or soft-tissue sarcoma before the age of 45, (2) a first-degree relative with any cancer under the age of 45, and (3) a firstdegree or second-degree relative in the same lineage with any cancer under the age of 45, or sarcoma at any age. 2 Upward of 75% of LFS patients develop cancers before the age of 45 as compared with 10% in the general population. 2 Moreover, cancer risk is estimated to be 90% by the age of 60 in patients with LFS. 2 Malignancies include sarcoma, breast, brain, leukemia, adrenal, lung, prostate, gastric, pancreatic, ampullary, lymphoma, germ cell tumors, and Wilms' tumor. 2 Recent National Comprehensive Cancer Network (NCCN) guidelines in oncology for genetic and familial highrisk assessment have addressed testing for LFS. 3 Testing criteria was divided into the classic LFS criteria and the Chompret criteria. 3 Classic criteria stated that testing should occur in individuals diagnosed with a sarcoma before the age of 45, who also have a first-degree relative diagnosed before the age of 45 with cancer, and also an additional first-degree or second-degree relative in the same lineage with cancer diagnosed before the age of 45, or a sarcoma at any age. 3 Chompret et al 4 revised this criteria stating TP53 mutation screening should be implemented in, an individual with a tumor from the LFS tumor spectrum before the age of 46 and at least 1 firstdegree or second-degree relative with any cancer of the LFS tumor spectrum other than breast cancer (if the proband has breast cancer) before the age of 56; an individual with multiple primaries at any age, an individual with ACC or choroid plexus carcinoma at any age of onset, regardless of family history, or an individual with early onset of breast cancer before the age of 30 with a negative BRCA1/BRCA2 test.
Surveillance was also addressed by the NCCN guidelines in oncology for genetic and familial high-risk assessment. Because of the prevalence of breast cancer among those with LFS, they advocated breast self-exam training and education starting at 18 years of age, clinical breast exams every 6 to 12 months, starting at the age of 20 to 25 years or 5 to 10 years before the earliest known breast cancer in the family. 3 Further, LFS patients should have annual mammography and breast MRI screening starting at the age of 20 to 25 years or individualized based on the earliest age of onset in family. 3 With respect to other cancer risks, the NCCN guidelines addressed the limitations of screening for many cancers associated with LFS and made a general statement that because of the remarkable risk of additional primary neoplasms, screening should be entertained for cancer survivors with LFS who have a good prognosis from their primary tumor. 3 As per NCCN, LFS patients should have annual comprehensive physical examinations (including careful skin and neurological exams) with a high index of suspicion for rare cancers and second malignancies in cancer survivors. 3 Colonoscopy should be considered every 2 to 5 years starting no later than the age of 25. 3 Participation in novel screening approaches using technologies within clinical trials when possible, such as wholebody MRI, abdominal US, and brain MRI is favored. 3 Overall, surveillance should be targeted based on individual family histories.
Three percent of LFS patients will develop ACC. 5, 6 Although chemotherapy (mitotane) is commonly used, it has little impact on disease progression. 7 Therefore, it is hypothesized that an aggressive surgical approach for ACC is associated with prolonged survival. 6, 7 Recently, Ripley et al 7 published the largest series to date of patients undergoing hepatic resection for metastatic ACC. This series found a median overall survival of 2 years, which was superior to historical controls. Extrapolating this data to our patient, we thought it is prudent to take an aggressive surgical approach to the metastatic ACC hepatic lesion. In addition, we felt the hepatic disease would be a rate-limiting step in this patient's overall survival. Fassnacht et al 8 recently published results of cytotoxic therapy in advanced ACC. They compared cytotoxic agents (etoposide, doxorubicin, cisplatin) plus mitotane versus streptozocin plus mitotane and found higher response rates (23.2% vs. 9.2%, P < 0.001) as well as increased progressionfree survival (5.0 vs. 2.1 mo, P < 0.001) in the cytotoxic group (Fassnacht 2012) . Adjuvant cisplatin-mitotane was implemented in our patient and may have suppressed a recurrence at her solitary portal vein inflow.
We advocated for a synchronous resection of the ampullary cancer with the patient's hepatic tumor. Currently, there are approximately 200 cases of combined PD and partial hepatectomy published. Recent reports stated that the procedure is safe and does not significantly increase ones morbidity as compared with PD alone. 9,10 Singh et al 9 analyzed 7 cases showing an increase in the amount of blood loss compared with PD alone; however, the overall complication rates and duration of hospital stay were not significantly affected.
PD itself carries a significant morbidity and mortality. Some believe that combining another procedure such as hepatectomy with PD makes it a formidable scenario. 9 However, with current improvements in surgical technique combined with improved perioperative and postoperative management, the morbidity and mortality of PD have decreased. 9 With these encouraging developments the limits of PD are being extended. Multivisceral resections combined with PD are now increasingly reported and have been proven safe when performed at experienced centers. 11, 12 Results of a systematic review of 103 patients undergoing synchronous PD and hepatectomy found that this procedure can be performed with low morbidity and mortality. 13 Furthermore, De Jong and colleagues analyzed 5025 patients who underwent PD at 2 large US hepatobiliary centers. Of this cohort, 126 patients underwent either staged or synchronous liver-directed therapy along with PD. It was concluded that a simultaneous approach should be used when possible for the incidence of hepatic abscess was increased in patients undergoing staged liver-directed therapy. 10 Although, the operative time may be prolonged and the complexity of the operation increased, the overall outcome remains relatively unaffected.
Radiation-associated cancers are typically rare, arising 10 years after irradiation and carry an incidence rate of <2%. 14 However, data suggests that LFS patients are at a higher risk of secondary radiation-induced malignancies. [14] [15] [16] [17] [18] Using breast cancer as an example, population analysis holds that the risk of locoregional relapse after breast surgery and adjuvant radiotherapy is reported to be 1% per year. 14 In a small cohort of LFS patients treated with breast conserving therapy for breast cancer, 3/8 patients developed a second malignancy (chest wall angiosarcoma, malignant histiocytofibroma, and papillary thyroid cancer) in the radiation field and 3/8 patients developed an in-field, ipsilateral breast relapse. 14 Hisada and colleagues also documented a relationship between radiotherapy and second malignancies in a cohort of 200 LFS patients. This study found that 8 solid cancers were diagnosed in 6 patients who had received radiotherapy. 15 The role of radiation stress in human cells containing heterozygous germline p53 mutations leads to a defective cell cycle arrest in G1/S and a lesser apoptotic response of lymphocytes. 14 These cellular features promote radiosensitization and potentially carcinogenesis. 14 In vivo analysis of Trp53 heterozygous null mice has found an accelerated emergence of solid tumors after ionizing radiation. 19 Because of the increased incidence of radiation-induced malignancy, a conservative approach should be undertaken for radiation therapy.
Long-term survival is achievable for LFS with multiple primaries and metastatic lesions when surgery is implemented in a multidisciplinary approach (Table 2) . 16, [20] [21] [22] [23] [24] For example, Izawa and colleagues published their experience with 1 patient who had 9 separate primary malignancies. Utilizing surgery the patient survived for over 20 years after her diagnosis of LFS. 22 Nutting et al 16 described a patient with LFS who had 17 different primary malignancies. Again, surgery was implemented and the patient had an overall survival of 41 years from her first malignancy. 16 Although the seven cases depicted in Table 2 are anecdotal reports without historical controls, we believe an aggressive surgical approach in LFS may prolong survival.
We propose, based on limited but promising data, that an aggressive surgical approach for tumor eradication should be undertaken in the LFS population with the principal aim of prolonging survival. Despite the paucity of data, and until proven otherwise, LFS patients presenting with multiple cancers and/or recurrences should undergo operations for each primary and/or recurrence as if it were the first cancer diagnosed. In essence, for a given cancer, one should treat LFS patients as one would treat non-LFS patients regardless of past occurrences; and, radiation therapy should be used conservatively, if at all, after thorough discussion with the patient.
